Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunoassays for Extrapulmonary Tuberculosis Need Improvement

By LabMedica International staff writers
Posted on 26 Aug 2013
The diagnosis of extrapulmonary tuberculosis (EPTB) is challenging as routine methods for diagnosis, such as smear for acid-fast bacilli (AFB) and culture of Mycobacterium tuberculosis on solid media, have poor sensitivity. More...


Nucleic acid amplification test and liquid culture methods are costly and required sophisticated infrastructure and therefore antibody based serodiagnosis tests for tuberculosis (TB) are used widely in developed and developing countries.

Scientists at the All India Institute of Medical Sciences (New Delhi, India) evaluated the diagnostic performance of commercially available enzyme-linked immunosorbent assay (ELISA) kit in the diagnosis of EPTB. They prospectively enrolled 354 patients, of whom 217 (61.2%) were EPTB patients and 137 (38.7%) were subjects with no suggestive TB, between 2007 and 2011. The mean age was 29.7 years for the EPTB patients and 31.2 years for the controls. Before culture inoculation, all samples were examined microscopically after Zeihl-Neelsen stain. All the isolates were confirmed as M. tuberculosis by species-specific in-house multiplex polymerase chain reaction (PCR) and phenotypic methods.

Three immunoglobulin based ELISA kits, PATHOZYME MYCO IgG, IgA, and IgM (Omega Diagnostics Limited; Alva, Scotland, UK) were used to check levels of antimycobacterial antibodies against two antigens in the serum of diseased and controls. The individual and overall sensitivity rates of IgM, IgA, and IgG assays were 29%, 24.4%, and 34.5%, respectively, while their specificities were 70.8%, 77.3%, and 68.6%, respectively. Not all TB patients produce antibodies against all antigenic epitopes in the cell walls of the tubercle bacilli, which infers on the inconsistency in specificity of antibody-based assays among different patient groups like gender, age, ethnicity, and geographical distribution.

The authors concluded that even though the specificity of the Pathozyme Myco IgA, IgM, and IgG was significantly better and acceptable as compared to pulmonary TB, the sensitivity of these kits was less than can be expected, and they did not recommend their use for diagnosis of EPTB. While a negative result by any one of these tests would be useful in helping to exclude disease in a population with a low prevalence of tuberculosis, a positive result may aid in clinical decision making when applied to symptomatic patients being evaluated for active tuberculosis. The study was published on August 1, 2013, in the Journal of Laboratory Physicians.

Related Links:

All India Institute of Medical Sciences
Omega Diagnostics Limited



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.